Real-life EValuation Of High Dose RosUvastatin in High Risk Patients After TitraTION

Completed

• Conditions: Hypercholesterolemia

• Registration Number: NCT00526721
• Lead Sponsor: AstraZeneca

Brief Summary

To evaluate achievement ratio of treatment target goal in hypercholesterolemia patients with high risk after high dose rosuvastatin(20mg/day) titration

Detailed Description

Not available

Study Timeline

• Study Start: 2007-05
• Study First Submitted: 2007-09-05
• Study First Submitted QC: 2007-09-06
• Study First Posted: 2007-09-10
• Primary Completion: 2008-04
• Study Completion: 2008-04
• Status Verified: 2012-03
• Last Update Submitted: 2012-03-19
• Last Update Posted: 2012-03-20

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 1482

Inclusion Criteria

• High-risk hyperlipidemia patients who are prescribed with rosuvastatin 10mg, based on the physician's clinical decision and fulfill the following criteria

  1. Over 18 years of age
  2. Have history of CHD or CHD risk equivalents, such as peripheral arterial disease, abdominal aortic aneurysm, symptomatic carotid artery disease (TIA or stroke of carotid origin or >50% obstruction of carotid artery), DM, and 2+ risk factors with 10-year risk CHD>20%

Exclusion Criteria

1. Patients already taking other hyperlipidemic agents
2. Patients who do not fulfil the indication criteria for statin therapy
3. Patients who do not have baseline and/or follow-up lipid data to verify the efficacy data

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Trial Locations

Locations (1)

Research Site; 🇰🇷 Seoul, Songpa-gu, Korea, Republic of